US in vitro diagnostics (IVD) industry struggling against odds
This article was originally published in Clinica
Striking the right balance between regulation and protecting public health is no easy task, Jim Benson, senior vice-president of US trade association HIMA, cautioned Chinese clinical laboratory managers and regulators. Addressing the Sino-American Conference on Clinical Laboratory Management in Beijing last week, he outlined some of the problems facing the $8 billion US IVD industry today - some 30 years after regulations were first put in place.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.